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Summary   
  
Voltage-gated sodium (NaV) channels, initially characterized in excitable cells, have been shown to be 
aberrantly expressed in non-excitable cancer tissues and cells from epithelial origins such as in breast, 
lung, prostate, colon, cervix, while they are not expressed in cognate non-cancer tissues. Their activity 
was demonstrated to promote aggressive and invasive potencies of cancer cells, both in vitro and in 
vivo, while their deregulated expression in cancer tissues has been associated with metastatic 
progression and cancer-related death. This review proposes NaV channels as pharmacological targets 
for anticancer treatments providing opportunities for repurposing existing NaV-inhibitors or developing 






Voltage-gated sodium (NaV) channels, composed of pore-forming NaVα and auxiliary NaVβ 
subunits, were initially characterized in excitable cells in which they are responsible for the triggering 
and the propagation of action potentials. Their physiological activity, through a transient depolarizing 
inward sodium current in cell types such as cardiomyocytes, skeletal muscle cells or neurons, is well 
characterized as being responsible for the initiation of excitation-contraction, excitation-secretion or 
excitation-expression couplings. As such, these ion channels are critical in numerous physiological 
functions and mutations in their encoding genes, as well as dysregulation of their activity, may lead to 
serious pathologies called “sodium channelopathies”. NaV channels are targets for multiple inhibitory 
molecules that are FDA-approved and clinically used in the treatment of pathologies such as cardiac 
angina or arrhythmias, epilepsies, chronic pain, or in anesthesiology.   
While the activity of NaV channels has been characterized about 70 years ago, recent data obtained in 
the past five years have shed light on the protein structure, arrangement and functioning at the 
molecular level. Indeed, the activity of NaV channels, i.e.  sodium currents (INa), was first recorded by 
Hodgkin and Huxley in 1952 from the squid giant axon, using the voltage-clamp technique. These 
pioneering experiments led to the ionic theory of membrane excitability (Hodgkin and Huxley, 1952). 
However, at that time the structure of NaV channels was not known and the first evidence of molecular 
properties came to light at the beginning of the 1980’s with the identification of the channel proteins 
using radio-labeled-neurotoxins highly selective for NaV channels in combination with protein 
solubilization and purification methods (Agnew et al., 1980, Beneski and Catterall, 1980). Further 
structural insights into NaV channels were obtained by cloning and screening of cDNA libraries leading 
to the discovery of the amino acid sequence for these proteins and allowing for modelling of secondary 
structures based on aliphatic profiles (Noda et al., 1986, Noda et al., 1984). These seminal studies 
allowed development of a model in which the pore-forming NaV principal subunit in eukaryotes, later 
called NaVα-subunit, is composed of a single polypeptide chain of approximately 260 kDa containing 
four repeated homologous domains (I-IV) of 6 transmembrane segments (S1-S6). This protein was 
identified to interact with one or two single-span transmembrane auxiliary subunits, called NaVβ-
subunits (30-40 kDa), initially characterized as bringing regulatory functions (Isom et al., 1994, Isom et 
al., 1992) to the macromolecular complex of eukaryotic NaV channels  (Brackenbury and Isom, 2011, 
Catterall, 2000).  
Interestingly, understanding of protein organization and function at the molecular level substantially 




first studying tetrameric prokaryotic channels sharing approximately 25-30% sequence identity with 
human channels. Thus information regarding the voltage-dependent gating, ion selectivity, drug 
binding, open, closed and inactivated states were acquired from the Arcobacter butzleri (NavAb) 
channel (Payandeh et al., 2012, Payandeh et al., 2011) (Lenaeus et al., 2017). The high-resolution 
crystal structure of the complete voltage-gated sodium channel (NaVMs) from Magnetococcus marinus 
was obtained in the activated open state, associated with electrophysiological recordings (Sula et al., 
2017). Recently, structural data obtained for NaVAb provided a complete gating mechanism for voltage 
sensor function, pore opening, and the activation-gate (Wisedchaisri et al., 2019). The first near-atomic 
resolution structure of a monomeric eukaryotic channel came from the recent study of the NaVPaS 
from the American cockroach, while structures of human voltage-gated sodium channel NaV1.2, NaV1.4 
and NaV1.7, in complex with β-subunits were recently published (Pan et al., 2018, Pan et al., 2019, Shen 
et al., 2019). These structural data provide important insight into mechanisms underlying NaV 
channelopathies and for drug discovery. Briefly, each domain presents two functional modules: S1-S4 
segments comprise the voltage-sensor module (VSM) while sections (S5 - P loop - S6) constitute the 
pore-forming module (PM). The positively charged arginine and lysine residues, positioned at every 
third residue within each S4 segment in the voltage-sensor module, sense changes in the 
transmembrane potential and transform this electrical stimulus into a fast conformational change of 
the pore-forming module, allowing the opening of the conductive pore, permitting Na+ influx. One to 
two milliseconds after pore opening, another fast voltage-dependent mechanism happens in the NaV 
channel protein, occluding Na+ influx, a process known as fast inactivation.   
Another recent study has challenged the initial paradigms by which functional channels contain a 
monomeric NaVα subunit. Indeed, NaVα-subunits appear to assemble as dimers and this physical 
interaction permits a coupled gating mechanism (Clatot et al., 2017). In humans, there are nine 
different genes encoding for NaVα-subunits, four of them clustered on chromosome 2: SCN1A (NaV1.1), 
SCN2A (NaV1.2), SCN3A (NaV1.3) and SCN9A (NaV1.7); three others located on chromosome 3: SCN5A 
(NaV1.5), SCN10A (NaV1.8) and SCN11A (NaV1.9); and two more located on chromosome 12 and 17: 
SCN8A (NaV1.6) and SCN4A (NaV1.4), respectively (Goldin, 2002). The amino acid sequence homology 
among NaV channels subtypes is higher than 70% in the transmembrane and extracellular motifs so 
that there are no distinct subfamilies, nonetheless, some of the isoforms are more closely related to 
each other, sharing chromosomal localization and sensitivity to tetrodotoxin (TTX), which has been 
explained by the early genomic duplication during the evolution of NaV channel genes. To date, four 
genes have been identified for NaVβ-subunits, one on chromosome 19: SCN1B (encoding for the two 




SCN2B (NaVβ2), SCN3B (NaVβ3) and SCN4B (NaVβ4). The structure of NaVβ-subunit is comprised of a N-
terminal extracellular immunoglobulin-like domain, followed by an extracellular juxtamembrane 
region, a single transmembrane segment and a 34-44 amino acid-length intracellular domain; except 
for the splice variant NaVβ1B, which is expressed as a soluble macromolecule (Brackenbury and Isom, 
2011). Furthermore, it is worth noting that NaVβ-subunits not only influence NaVα-subunit trafficking 
and biophysical modulation but they have also been experimentally shown to act as cell adhesion 
molecules (CAMs), participating in both homophilic and heterophilic interactions, with contactin, N-
cadherin, NrCAM, several types of neurofascin and tenascin being the main binding proteins (Isom, 
2002, Bouza and Isom, 2018).   
NaVα and NaVβ subunits are differentially and developmentally expressed in several tissues and cell 
types (Black and Waxman, 2013, Roger et al., 2015). Initial studies identified NaV to be distributed in 
excitable tissues such as in mammalian central and peripheral nervous systems as well as in skeletal 
and cardiac muscle. The central nervous system channels mainly comprise the NaV1.1, NaV1.2, NaV1.3 
and NaV1.6 isoforms; while the peripheral nervous system channels include NaV1.7, NaV1.8 and NaV1.9. 
NaV1.4 and NaV1.5 were characterized as being the main skeletal and heart muscle isoforms, 
respectively (Goldin, 2001), while they also have been identified to be expressed the brain and in the 
dorsal root ganglion (Wang et al., 2008, Wang et al., 2009, Wang et al., 2018a, Wang et al., 2018b, 
Bergareche et al., 2015). Therefore, the expression of NaV has long been considered as the hallmark of 
excitable cells. Again, this paradigm has recently changed with the identification of expression (mRNA 
and protein) and sometimes activity at the plasma membrane (transient sodium currents) in non-
excitable tissues and cells such as in chondrocytes, endothelial cells, microglia, astrocytes, fibroblasts, 
keratinocytes, islet β-cells, red blood cells, T-lymphocytes, dendritic cells and macrophages, among 
others, in which the biological role and subcellular distribution of Navs is still elusive (Black and 
Waxman, 2013, Roger et al., 2015) .  
Recently, it has emerged that NaVα channels, as well as auxiliary NaVβ subunits, are aberrantly 
expressed in non-excitable cancer tissues and cells from different epithelial origins such as breast, lung, 
prostate, colon, cervix, while they are not expressed in cognate non-cancer tissues. Their expression in 
carcinoma cells has been associated with cancer progression, suggesting that they could serve as 
cancer markers and prognostic factors. The expression and activity of NaV channels was shown to 
promote pro-cancerous properties and, importantly, to contribute to disease progression, in both in 
vitro and in vivo models. Recent studies shed light on the signaling pathways that are under the control 
of these channel proteins, coupling membrane activity to cellular properties. Furthermore, the 




with natural dietary compounds potentially opens up new therapeutic strategies. In this review, we 
summarize current knowledge on the expression of NaV channels in cancers, highlight the signaling 
pathways involved, and discuss pharmacological and nutritional strategies that represent 
opportunities for novel anticancer treatments.  
  
 I-  The aberrant expression of NaVα and NaVβ subunits in cancers  
The expression of voltage-gated sodium channel subunits, both NaVα and NaV β, has been reported 
to be altered in several types of cancer. The channel subunits have been detected by molecular biology 
and biochemical techniques, and in multiple cancer types NaV activity at the plasma membrane, i.e. INa, 
could be recorded. Most subunits have been shown to be up-regulated in cancers, while some of them 
appear to be downregulated. This aberrant expression has been correlated with oncogenic properties 
in both in vitro and in vivo models of cancer, mostly in solid tumours including carcinomas (Figure 1).  
  
a- NaVα and NaVβ subunits in Prostate cancer  
While early works assessing ion channel activity identified sodium currents in small-cell lung cancer 
cells (Pancrazio et al., 1989), the first report of the direct contribution of NaV channels in cancer 
properties came from work performed in prostate cancer (PCa) cells by Prof. M. Djamgoz’ group almost 
25 years ago. This first study was performed in two rat prostatic tumour cell lines in which they found 
a differential expression of voltage-activated Na+ currents: highly metastatic Mat Ly-Lu cells expressed 
Na+ currents, whereas weakly metastatic AT-2 cell, did not express this type of current. For the first 
time, the functional relevance of the Na+ current was demonstrated: blocking INa with nanomolar 
concentrations of TTX reduced by ∼30% the invasiveness of the highly metastatic Mat-Ly-Lu cells 
(Grimes et al., 1995). Further evidence showed that the NaV1.7 pore-forming subunit, encoded by the 
SCN9A gene, was overexpressed in highly metastatic human and rat prostate cell lines in comparison 
with weakly metastatic cell lines (Diss et al., 2001). Later, this observation was confirmed in vivo by 
showing that NaV1.7 was overexpressed approximately 20 times in PCa biopsies versus non-cancer 
samples (Diss et al., 2005). Finally, in a rat model, inoculation with highly metastatic Mat-Ly-Lu cells 
promotes prostate cancer metastasis in vivo, and blockade of NaV in primary tumours with TTX (Yildirim 
et al., 2012) or ranolazine (Bugan et al., 2019) reduced lung metastases by 40% and 63%, respectively. 




show a positive correlation between mRNA/protein of NaV1.7 upregulation and human PCa patient 
samples.  
Concerning NaVβ subunits, it was shown that NaVβ1 mRNA was the most highly expressed in strongly 
invasive compared to weakly invasive PCa cell lines (Diss et al., 2008). However, there was no significant 
difference in the expression of NaVβ1, or any other NaVβ subunits, between cancer and non-cancer 
human prostate specimens (Diss et al., 2008). NaVβ2 has been proposed to participate in prostate 
cancer biology. Indeed, the first experimental observation showed that the overexpression of NaVβ2, 
fused to GFP, was properly localized at the plasma membrane of weakly metastatic LNCaP cells 
inducing morphological changes consistent with a bipolar and elongated migratory phenotype (Jansson 
et al., 2012). These changes were accompanied by an increase in cell migration and Matrigel invasion 
in vitro, although there was no significant change in cell proliferation. However, the in vivo properties 
of LNCaP cells overexpressing the NaVβ2 subunit were quite unexpected as subcutaneous tumour 
volume was drastically reduced compared to the control group (Jansson et al., 2012). Such contrasting 
effects could imply different mechanisms involved in tumour formation, growth and metastatic 
behaviour. A novel ex vivo organotypic spinal cord co-culture with LNCaP cells revealed that 
overexpression of NaVβ2 enhanced the association of PCa cells with nerve axons (Jansson et al., 2014). 
Furthermore, overexpression of NaVβ2 enhanced PCa cell migration, invasion, and growth, in the 
presence of the neuronal CAM laminin, suggesting that the NaVβ2 subunit may mediate metastatic 
behaviour through association with neural substrates (Jansson et al., 2014).  
  
b- NaVα and NaVβ subunits in breast and colorectal cancer  
Breast cancer (BCa) is the most lethal female cancer worldwide (Bray et al., 2018) and colorectal 
cancer (CRCa) is the third most commonly diagnosed cancer (Arnold et al., 2017). The incidence of 
these cancers is gradually increasing, thus representing a serious global health problem. The main 
cause of patient mortality from these two types of cancers, as for the majority of carcinomas, is the 
development of metastases in distant organs, following the dissemination of cancer cells from the 
primary tumour (Figure 1).  
Multiple studies have investigated the expression of NaV channels and their contribution to tumour 
progression and metastasis in BCa and CRCa. Knowledge about signalling pathways and cellular 
mechanisms induced by NaV channels have been mostly acquired from these cancers. In both cases, 




overexpressed as compared to normal tissues (Fraser et al., 2005). A high expression was correlated 
with cancer recurrence, metastasis development and reduced patient survival (Yang et al., 2012). Most 
of the mechanistic studies in BCa have been performed in human cancer cell lines like MDAMB-231 
(highly metastatic) and compared with weakly metastatic cell lines like MCF-7. It has been shown 
initially shown that MDA-MB-231 express a TTX-resistant Na+ current, lacking in MCF-7 cells (Roger et 
al., 2003), which is encoded by a neonatal splice variant of the SCN5A gene (Fraser et al., 2005). This 
neonatal variant is due to a switch from adult exon 6B to foetal exon 6A, which are mutually exclusive 
and encode for a part of the voltage sensor, segments 3 and 4 located in the domain I of the channel. 
Therefore, these two variants, called hNaV1.5 and hNaV1.5e for the adult and the neonatal channels 
respectively, show different electrophysiological properties in terms of voltage-sensitivity and current 
kinetics (Murphy et al., 2012, Onkal et al., 2008). These changes result in a greater Na+ influx for 
neonatal hNaV1.5e (Onkal et al., 2008). In the heart, splicing of SCN5A is developmentally regulated, 
such that the neonatal exon 6A is rapidly replaced by the “adult” exon 6B after birth (Murphy et al., 
2012) and molecular determinants explaining the abnormal expression of hNaV1.5e in cancer cells 
have not been identified so far. Nevertheless, the inhibition of channel activity, by either 
pharmacological (TTX, ranolazine and phenytoin) or molecular (siRNA and inhibitory antibody) 
approaches, have shown its contribution to migration and invasion of BCa cell lines (Roger et al., 2003, 
Fraser et al., 2005, Brackenbury et al., 2007, Driffort et al., 2014, Yang et al., 2012). There has also been 
some significant progress into uncovering the mechanisms underlying the promotion of invasiveness 
behaviour by NaV1.5. Experimental evidence suggested that NaV1.5 induces pro-migratory and pro-
invasive properties through a persistent activity at the membrane potential called “window current”, 
and a correlated depolarisation of the membrane voltage of breast cancer cells. Particularly, NaV1.5 
activity induced the allosteric modulation of the Na+-H+ exchanger type 1 (NHE-1), resulting in an 
increased activity leading to the acidification of the extracellular space, thus favouring the pH-
dependent activity of proteolytic cysteine cathepsins (Gillet et al., 2009, Brisson et al., 2011). In 
addition, NaV1.5 expression and activity were demonstrated to increase Src kinase activity, which 
promotes the acquisition of an invasive morphology (invadopodia) in MDA-MB-231 cells. Taken 
together, these observations indicate that NaV1.5 promotes invadopodia activity of breast cancer cells 
and the invasion of the surrounding ECM (Brisson et al., 2013) (Figure 1). Recently, NaV1.5 was 
identified as importantly promoting the epithelial-to-mesenchymal transition (EMT) and cancer cell 
invasiveness through the regulation of the Salt-inducible kinase 1 (SIK1) (Gradek et al., 2019). 
Furthermore, NaV1.5 activates the small GTPase Rac1 by sustaining a plasma membrane 
depolarization, which as a regulator of activation, induces cytoskeletal reorganization and cellular 




metastasis in immunodeficient mice (Driffort et al., 2014, Nelson et al., 2015a, Nelson et al., 2015b). 
NaV1.5 activity also increases MMP9 expression and reduces apoptosis in primary tumours in vivo 
(Nelson et al., 2015b).  
The SCN5A gene and its protein product the NaV1.5 channel have also been shown to be overexpressed 
in colorectal cancer biopsies, as compared to non-cancer samples (House et al., 2010). NaV1.5 was 
found to be expressed at the plasma membrane of tumour cells, and its activity (INa) was recorded 
several carcinoma cell lines (mainly SW-480, SW-620 and HT-29) (House et al., 2010). In colon cancer 
cells, NaV1.5 activity promotes cancer cell invasion in vitro, in both 2- and 3-dimension models and 
regulates a network of invasion-promoting genes via modulation of the PKA/ERK/cJUN/ELK-1/ETS-1 
transcriptional pathway (House et al., 2010, House et al., 2015, Poisson et al., 2020) (Figure 2). It was 
shown that, similar to BCa, the neonatal exon 6A splice variant of the NaV1.5 isoform has a 
predominant contribution to the invasiveness of CRCa cell lines (Guzel et al., 2019), even though both 
adult hNaV1.5 and neonatal hNaV1.5e splice variants could be detected (Baptista-Hon et al., 2014).   
A study reported the downregulation of the SCN9A gene, encoding for NaV1.7, in CRCa (Pan et al., 
2017). In this study, authors analysed genes differentially expressed in CRCa utilizing three Gene 
Expression Omnibus (GEO) data sets. By screening 46 biomarkers associated with cancer proliferation, 
drug-resistance and metastasis, i.e., genes closely associated to patient overall survival, they proposed 
a risk score with high prognostic value based on the expression of five genes: MET (MET proto-
oncogene and receptor tyrosine kinase), CPM (carboxypeptidase M), SHMT2 (serine 
hydroxymethyltransferase 2), GUCA2B (guanylate cyclase activator 2B), and SCN9A. MET, SHMT2 were 
up-regulated while CPM, GUCA2B and SCN9A were down-regulated. Interestingly, this observation was 
confirmed in the human protein atlas immunohistochemistry database (www.proteinatlas.org), as the 
staining for NaV1.7 was lower in some CRCa sample tissues (Pan et al., 2017). There are also reports 
indicating the downregulation of NaV1.6, encoded by the SCN8A gene, in CRCa (Igci et al., 2015). 
Tumour samples from CRCa patients exhibited reduced expression of NaV1.6 compared with paired 
tumour-surrounding normal tissues. SCN8A mRNA levels, analysed by real-time qPCR, were 
significantly lower in tumour tissues and in patients aged below 45 years. Results also reveal a 
relationship between SCN8A expression, gender, grade of CRCa, tumour location and histopathological 
classification (Igci et al., 2015). On the contrary, NaV1.6 protein was highly expressed in metastatic 
lymph nodes from CRCa patients (Lin et al., 2019).  While the reduced expression of SCN8A, encoding 
for NaV1.6, and SCN9A, encoding for NaV1.7 might harbour predictive values in CRCa, we are still 
missing clear information to assert whether they have a role, either causative or consecutive, in the 




or progression. Indeed, the functional activity of NaV1.6 and/or NaV1.7 at the plasma membrane of 
colorectal non-cancer or cancer cells has not been demonstrated so far. Furthermore, it cannot be 
excluded that these channels might be expressed in intracellular compartments, in which they might 
play diverse functions. Eventually, it is not clear at the moment whether these changes in expression 
levels concern epithelial cells, or non-epithelial cells in the colorectal tract, such as immune cells which 
are key protagonists in colorectal carcinogenesis. As such, the participation of SCN8A and SCN9A in 
CRCa biology will require further studies.    
  
The expression of NaVβ subunits has been studied in BCa and in CRCa. Some NaVβ have been 
shown to be up-regulated while others are down-regulated in cancer tissues, and mostly these changes 
appear to correlate with the metastatic behaviour of cancer cells, in particular with cell migration and 
invasion. Most research performed so far studying the role of NaVβ subunits in metastatic behaviour 
has been undertaken in BCa. Originally, it was shown that NaVβ1 was more abundantly expressed in 
the weakly metastatic MCF-7 than in the highly metastatic MDA-MB-231 cell line. Interestingly, when 
MCF-7 cells were transfected with specific siRNA directed against NaVβ1, cell adhesion was reduced by 
35%, while migration was increased by 121%. In contrast, stable expression of NaVβ1 in MDA-MB-231 
cells increased process length and adhesion while reducing lateral motility and proliferation. Thus, 
NaVβ1 was proposed to act as a cell adhesion molecule in BCa cells, negatively controlling cellular 
migration (Chioni et al., 2009). Later, it was found that NaVβ1 was the NaVβ subunit most expressed in 
BCa and was up-regulated (both mRNA and protein) in BCa biopsies, compared with normal breast 
tissue (Nelson et al., 2014, Bon et al., 2016). More importantly, by using a xenograft model of BCa, it 
was shown that NaVβ1 overexpression increased tumour growth, metastasis, and vascularization, while 
decreasing apoptosis in the primary tumours. Therefore, this study was the first showing the functional 
role for NaVβ1 in tumour growth and metastasis in vivo (Nelson et al., 2014). Consistent with these 
results, the use of siRNA to specifically target NaVβ1 expression in MDA-MB-231 cells inhibited cancer 
cell invasion (Bon et al., 2016).  
The participation of NaVβ3 in tumorigenesis process is poorly understood. Two missense mutations 
have been identified in the SCN3B gene in high grade metastatic colorectal cancer biopsies (Sjoblom 
et al., 2006).  The first report suggested that non-mutated NaVβ3 mediates a p53-dependent apoptotic 
pathway in Saos-2, a bone osteosarcoma cell line, after DNA damage (Adachi et al., 2004). In agreement 
with this, the SCN3B gene is not expressed in highly invasive MDA-MB-231 breast cancer cells (Gillet et 




expression was the lowest among all NaVβ encoding genes, and was still significantly reduced in cancer 
samples (Bon et al., 2016).  
The SCN4B gene was shown to play a critical role as a metastasis-suppressor gene in BCa (Bon et al., 
2016).  In this study SCN4B mRNA appeared to be significantly expressed in normal breast, colon, 
rectum, lung and prostate but consistently downregulated in cancer samples. Furthermore, NaVβ4 
protein was expressed in normal epithelial cells but significantly reduced in BCa biopsies, especially in 
high-grade primary and metastatic tumours. In vitro experiments showed that reducing NaVβ4 
expression potentiates cell migration and invasiveness though an increase in RhoA activity and the 
acquisition of a hybrid mesenchymal-amoeboid aggressive phenotype. This effect was independent of 
NaVα channel activity and was prevented by overexpression of the intracellular C-terminus of NaVβ4. 
On the contrary, SCN4B overexpression reduced cancer cell invasiveness and tumour progression. The 
findings are in line with previous observations showing decreased levels of SCN4B in invasive versus 
non-invasive PCa cells (Diss et al., 2008). Interestingly, a recent study identified dysregulated miRNA in 
CRCa and reported an increased miR-424-5p expression in tumour samples that was associated with 
poor prognosis (Dai et al., 2020). miR-424-5p was found to be elevated in the peripheral blood of CRCa 
patients, most probably secreted in tumour exosomes. In this study, it was demonstrated that 
overexpression of SCN4B inhibited HT-29 CRCa cell proliferation, migration and invasion and 
expression of SCN4B was directly inhibited by miR-424-5p (Dai et al., 2020). These results support the 
tumour-suppressor role of SCN4B in CRCa and identified miR-424-5p as a regulator of its expression in 
tumours.  
  
c- NaVα and NaVβ subunits in Lung cancer   
There are two subtypes of lung cancer, small-cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC). Early works assessing ion channel activity have been undertaken in small-cell lung cancer cells. 
In these pioneering works, INa was initially recorded in human H146, H69 and H128 small-cell lung 
cancer cell lines (Pancrazio et al., 1989), although this study did not relate the presence of NaV currents 
to lung tumorigenesis process itself. These currents were most probably due to TTX-sensitive channels 
since they were fully inhibited by 5 µM TTX. While neither the molecular characterization of the 
channels nor their biological role were described, they were proposed to participate in a 
“neuroendocrine-like” tumour cell phenotype (Pancrazio et al., 1989). Later, it was shown that these 
sodium currents were actually able to participate in the generation of action potentials in H146 SCLC 




the contribution of a TTX-resistant current (Blandino et al., 1995). In fact, H146 cells, sodium currents 
demonstrated an IC50 to TTX of 215 nM, leading the authors to indicated that NaV channels were weakly 
TTX-sensitive. However, this concentration is too high to consider the channels to belong to the TTX-S 
category but too low to belong to TTX-R isoforms. The most likely explanation for this would be the 
expression of a population of different isoforms of NaV at the plasma membrane of cells, thus leading 
to an apparent IC50 that would be intermediate between TTX-S and TTX-R. Nevertheless, it cannot be 
excluded the possibility that NaV channels expressed in these cells are variants (splice-variants or 
polymorphism variants) showing specific pharmacological properties.  
The hypothesis of the role of NaVα in the acquisition of a neuroendocrine phenotype was also proposed 
by M. Djamgoz’s team (Onganer et al., 2005). Unexpectedly, in this later study, the endocytic activity 
of SCLC cells was inhibited by using lower nanomolar concentrations of TTX, suggesting the 
participation of TTX-sensitive sodium channels in these SCLC cells. In addition, they found mRNA 
encoding for NaV1.3, NaV1.5 and NaV1.6 in H69, H209 and H510 cell lines. The latter also showed the 
additional presence of NaV1.9 mRNA. Thus, it remains to be elucidated which NaV subunit is responsible 
for the generation of TTX-resistant action potentials in H146 cells (Blandino et al., 1995), and whether 
a TTX-resistant NaV channels contribute to migration, invasion or some other metastatic component, 
other than endocytic activity (Onganer et al., 2005), in SCLC cell lines. More studies are needed 
investigating the expression profile and role of NaV channels in SCLC biopsy tissue.  
Later analyses were also performed in non-small cell lung cancer (NSCLC) in which the NaV1.7 isoform 
was shown to potentiate cancer cell invasion (Roger et al., 2007, Campbell et al., 2013). Although 
different NSCLC cell lines (H23, H460, and Calu-1) express mRNA for several Na+ channel isoforms 
(Roger et al., 2007), the selective inhibition of NaV1.7 activity (using TTX) or reduction of expression (by 
using small interfering RNA), reduced H460 cell invasion by up to 50%. On the contrary, weakly invasive 
A549 cells showed no evidence of functional NaV channels (Roger et al., 2007). In addition, exogenous 
overexpression of the NaV1.7 subunit was sufficient to promote TTX-sensitive invasion of these cells. 
Interestingly, NaV1.7 protein expression was found to be higher in cancerous compared to normal-
matched human lung tissue (Campbell et al., 2013). It is worth noting that at least in one NSCLC cell 
line (Calu-1), expression of a TTX-resistant NaV channel significantly contributes to the invasion capacity 
of this strongly metastatic cell line. However, the molecular identity of the molecular mediator of INa 
has not been fully characterized. Non-quantitative PCR results suggested that mRNAs encoding the 
three known TTX-resistant NaV channels (NaV1.5, NaV1.8 and NaV1.9) may be more abundantly 
expressed in Calu-1 than in H23 and H460 cells (Roger et al., 2007). While kinetics and TTX-sensitivity 




identify the molecular identity of the NaV channels mediating the Na+ current in these cells. In addition, 
there are currently no data correlating NaVα expression in lung cancer tissue with clinical outcome.          
  
The expression of NaVβ in LCa has been assessed in several studies but so far it is difficult to conclude 
a general pattern. SCN1B mRNA was found to be expressed in H460, Calu-1 and A549 but not in the 
H23 NSCLC cell lines. It was also expressed in non-cancer NL-20 and BEAS-2B cells. SCN2B appeared to 
be weakly expressed in A549 cancer and NL-20 non-cancer cells while not expressed at all in H23, H460 
and Calu-1 cancer cell lines. SCN3B mRNA was found to be expressed in all these cell types with the 
only exception of H460. SCN4B mRNA was expressed in cancer H23 and non-cancer NL-20 and BEAS-
2B, but not in H460, Calu-1 and A549 (Roger et al., 2007). In patient samples, SCN4B expression levels 
were downregulated in lung cancer compared with normal lung tissue and preliminary 
immunohistochemical analyses in lung cancer tissue microarrays showed a tendency towards 
decreased protein expression in high-grade primary lung tumours and metastases (Bon et al., 2016). 
The role of the NaVβ1 protein in cell adhesion was also proposed in human non-small cell lung cancer 
cell lines (Campbell et al., 2013). In this study, it was shown that the highly invasive H460 cells exhibited 
very low expression of all NaVβ subunit mRNAs, confirming previous results (Roger et al., 2007), 
whereas A549 cells expressed 8-fold higher levels of NaVβ1 mRNA. Accordingly, cell adhesion was two-
fold higher in A549 cells compared to H460 cells (Campbell et al., 2013). Moreover, manipulation of 
NaVβ1 mRNA expression by using siRNA or cDNA targeting SCN1B in these two cell lines, confirmed the 
contribution of this subunit in the promotion of cell adhesion and reduced invasion (Campbell et al., 
2013).  
  
d- NaVα and NaVβ subunits in gastric cancer   
In gastric cancer (GCa) tissue samples and in two human GCa cell lines (BGC-823 and MKN-28 cells), 
it was shown that the SCN9A gene, encoding NaV1.7, is the most abundantly expressed NaVα isoform 
(Xia et al., 2016). A systematic evaluation of 319 GCa tumour tissue samples by immunohistochemistry 
revealed a correlation of NaV1.7 expression with poor prognosis, as well as correlation with the 
expression of the with NHE1 exchanger type 1 and the oncoprotein metastasis-associated in colon 
cancer-1 (MACC1). In addition, NaV1.7 suppression resulted in reduced invasion and proliferation rates 
of GC cells and growth of GC xenografts in nude mice (Xia et al., 2016). In brief, results of this study 





e- NaVα and NaVβ subunits in Cervical Cancer (CeCa)  
The product of the SCN8A gene, the NaV1.6 channel, has been shown to be upregulated in cervical 
cancer (CeCa). In a study performed by using primary cultures derived from three different patient 
CeCa biopsies, the presence of functional NaV channels has been identified and INa recorded. Primary 
cells from CeCa biopsies expressed mRNA for different TTX-sensitive NaVα subunits: NaV1.1-1.4, NaV1.6 
and NaV1.7 (Diaz et al., 2007). Among these, only the SCN8A gene encoding for NaV1.6 was shown to 
be over-expressed by about 40-fold at the mRNA level in CeCa primary cultures and biopsies in 
comparison with non-cancerous cervical tissue. The functional relevance of this NaV channel was 
demonstrated by blocking its activity with TTX as well as with the Cn2 specific toxin, which in both cases 
led to a significant decrease in the invasion capacity of CeCa primary culture cells, without affecting 
proliferative or migratory cell behaviour (Hernandez-Plata et al., 2012). This suggested a role for NaV1.6 
in extracellular matrix degradation, and indeed NaV1.6-mediated invasiveness of CeCa cells specifically 
involved MMP-2 activity along with increased expression of the NHE1 exchanger (Lopez-Charcas et al., 
2018). In addition, CeCa cell lines more abundantly express the mRNA for the NaV1.6 variant which has 
exon 18 deleted (∆18 variant) rather than the neonatal and adult splice variants. This variant appeared 
to be distributed in intracellular compartments (Lopez-Charcas et al., 2018). However, the functional 
relevance of the ∆18 variant to the metastatic behaviour of CeCa cells remains to be elucidated. 
Another, interesting question regarding the expression of this ∆18 variant of NaV1.6 in CeCa cells is 
whether it has the same function in intracellular compartments as observed in macrophages and 
melanoma cells in which the channel has a role in podosome formation and activity (Carrithers et al., 
2009).  
          
The role of NaVβ1 as a migration suppressor gene was demonstrated in three different CeCa cell 
lines (HeLa, SiHa and CaSki) in which SCN1B mRNA levels were around 3- to 6-fold higher than those of 
NaVβ2, NaVβ3 or NaVβ4. However, differences in protein levels among the four NaVβ subunits were 
more discrete; NaVβ1 was again the most highly expressed in HeLa and CaSki cells, whereas in SiHa 
cells, protein levels for all NaVβ were more uniform (Sanchez-Sandoval and Gomora, 2019). Previously, 
the same group had demonstrated that NaVβ1 mRNA levels were also slightly higher in CeCa biopsies 
than in non-CeCa tissue (Hernandez-Plata et al., 2012). In addition, it was demonstrated that NaVβ1 




cell cycle (Sanchez-Sandoval and Gomora, 2019). Because NaVβ3 was proposed to have anti-cancer 
properties (Adachi et al., 2004), the effect of its expression in CeCa cells was tested. However, neither 
its overexpression nor its downregulation affected proliferation in CeCa cell lines, suggesting that the 
likely pro-apoptotic activity of NaVβ3 might not be a generalized mechanism in all cancer types or cells. 
In this regard, it has been suggested that the p53 protein status in CeCa cell lines is under the control 
of the E6 protein, the main oncogene expressed as a result of human papillomavirus (HPV) infection 
(the most frequent risk factor for CeCa incidence) of cervical epithelial cells. The early expression of E6 
protein leads to the specific ubiquitination and degradation of p53 (Scheffner et al., 1993), therefore 
inactivating any pro-apoptotic effect due to the NaVβ3 expression in basal conditions. In line with this 
interpretation, SCN3B expression was increased almost 2-fold in CeCa biopsies when compared to non-
cancer samples (Hernandez-Plata et al., 2012). Further studies are needed to fully understand the 
potential role of SCN3B as well as the mechanism involved in the pro-apoptotic effect in cancer cells. 
More recent observations in CeCa cell lines confirm the contribution of NaVβ4 to cell invasive potential 
as the downregulation of SCN4B leads to an increase in the percentage of invading cells in three CeCa 
cell lines (Sanchez-Sandoval and Gomora, 2019). However, a previous study indicated that mRNA levels 
for NaVβ4 were not significantly different between CeCa and non-CeCa biopsies tissues (Hernandez-
Plata et al., 2012).  
  
f- NaVα subunits in Ovarian cancer and endometrial cancers   
In ovarian cancer (OCa), the NaV1.5 isoform appears to be the main NaVα subunit expressed and 
contributing to the migration and invasion capabilities of cancer cells (Gao et al., 2010, Liu et al., 2018), 
however, the splicing status of NaV1.5 in this carcinoma, is currently unknown.  
In endometrial cancer tissues, a recent study identified the SCN9A gene, encoding for the NaV1.7 
channel, as being the most highly expressed NaVα subunit. NaV1.7 expression level was associated with 
tumour size, local lymph node metastasis, and 5-year and 10-year survival. Pharmacological inhibition 
using the PF-05089771 blocker selective for NaV1.7 and NaV1.8, induced cancer cell apoptosis and 
reduced cancer cell invasion (Liu et al., 2019).  
  
g- NaVβ in Papillary thyroid cancer   
Recent results obtained in papillary thyroid cancer (PTC) show that SCN4B is downregulated at both 




using databases like the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA)Thyroid 
Cancer (THCA), the authors found that SCN4B expression was an independent indicator of favourable 
recurrence-free survival (RFS) in patients with classical PTC, further contributing to the notion of the 
SCN4B as a metastases-suppressor gene (Gong et al., 2018). So far, nothing is known about the 
expression of NaVα subunits in PTC.  
  
h- NaVα and NaVβ subunits in Leukaemia cells  
While most results related to NaV in cancer were obtained from solid tumours, predominantly 
carcinomas, there are also some indication that NaV expression might also be dysregulated in 
haematological disorders such as leukaemia, in which they could bear oncogenic properties. In Jurkat 
leukemic T-cell lymphoblasts, original evidence showed that a small fraction of ~10% displayed INa, and 
mRNA encoding for NaV1.5, NaV1.6, and to a lesser extent NaV1.7 and NaV1.9, were detected (Fraser et 
al., 2004). INa was likely carried mostly by a TTX-resistant NaV channel since an IC50 of ∼1 µM was 
measured. Importantly, invasion was reduced by 93% when the cells were treated with 10 µM TTX 
(Fraser et al., 2004). However, more recent data has shown that NaV1.6, NaV1.7 and NaV1.3 (in that 
order) are the most abundant NaV isoforms in three acute lymphocytic leukaemia cell lines, including 
Jurkat, MOLT-4 and BALL-1 cells, as well as in peripheral blood mononuclear cells (PBMC). In this study, 
INa recorded from approximately 20% of MOLT-4 cells was completely abolished by 2 µM TTX, indicative 
of TTX-sensitive channels. The same concentration of TTX decreased the invasion of MOLT-4 and Jurkat 
cells by 90% (Huang et al., 2015).   
Interestingly, semi-quantitative PCR results indicated the presence of both the neonatal (18N) and the 
∆18 (exon 18 skipped) isoforms of NaV1.6 channel in the THP-1 monocytic leukaemia cell line 
(Carrithers et al., 2009). Neither of these two variants form functional channels at the plasma 
membrane (Plummer et al., 1997). Instead, the ∆18 NaV1.6 channel isoform is expressed in vesicular 
intracellular compartments and crucially contributes in the control of podosome and invadopodia 
formation (Carrithers et al., 2009). In addition, SCN5A (NaV1.5) is expressed in the late endosome, 
rather than at the plasma membrane of the THP-1 cells. The intracellular NaV1.5 channel was shown 
to enhance endosomal acidification and phagocytosis (Carrithers et al., 2007), Ca2+ signalling and 
phenotypic differentiation in human macrophages (Carrithers et al., 2011). The same group later 
demonstrated that SCN5A was expressed as a new splice variant lacking exon 25, resulting in a deletion 
of 18 amino acids in domain III (Rahgozar et al., 2013), generating non-selective outward currents and 




   
i- NaVα in Ewing Sarcoma    
The Ewing Sarcoma (ES) is the second most common primary malignant bone tumour in children and 
adolescents, following osteosarcoma (Choi et al., 2014). RING1B, a member of the Polycomb family of 
epigenetic regulators, is highly expressed in primary ES tumours. Depletion of RING1B with shRNA in 
ES cells enriched the expression of genes involved in haematological development, without affecting 
cellular differentiation (Hernandez-Munoz et al., 2016). Importantly, in ES cells, RING1B directly binds 
to the promoter of SCN8A and its depletion results in enhanced NaV1.6 expression and function. In 
addition, the migratory speed of RING1B-depleted ES cells was attenuated, suggesting an inverse 
correlation between SCN8A expression and the migration capabilities of ES cells. Finally, reduced 
NaV1.6 function appeared to protect ES cells from apoptosis by a mechanism that maintains low NF-κB 
levels (Hernandez-Munoz et al., 2016). These findings revealed striking differences in the participation 
of SCN8A and its product, the NaV1.6 channel, in sarcomas compared to carcinomas and leukaemia. 
Indeed, NaV1.6 appeared to have anti-cancer properties in ES while it has pro-invasive functions in 
carcinomas and leukaemia. Therefore, further studies are needed to fully understand the function of 
SCN8A across different types of cancer.  
  
II-  Conclusions on the roles of NaVα and NaVβ subunits in cancers a- 
Pore-forming NaVα subunits  
As previously indicated, the three main NaVα-encoding genes found to be upregulated in cancers 
are SCN5A, SCN8A, and SCN9A, which encode NaV1.5, NaV1.6 and NaV1.7 respectively. On the other 
hand, recent reports showed the downregulation of SCN8A and SCN9A genes in some cases. The 
molecular determinants explaining why these specific isoforms are overexpressed in cancers are not 
known and might be tissue-specific. However, it is tempting to consider the deregulation in tumours 
of transcription factors which normally restrict the expression of a suite of genes associated with 
specific tissue functioning in adult tissues, such as the repressor element silencing transcription factor 
(REST) which restrict the expression of NaVα channels in excitable cells (Bruce et al., 2004, Chong et al., 
1995) or other epigenetic regulations such as histone acetylation/deacetylation (performed by Histone 
Acetylases HAT and Histones Deacetylases HDAC, respectively), DNA or histone methylation. Indeed, 
it was recently proposed that REST and HDAC2 play important role as epigenetic regulators and their 
inhibition in MCF-7 breast cancer cells enhanced the expression of NaV1.5 and promoted invasive 




studied in cancer cells, several neonatal splice variants of channels have been identified (Fraser et al., 
2005, Lopez-Charcas et al., 2018, Baptista-Hon et al., 2014, Carrithers et al., 2009), thus supporting the 
common hypothesis of the re-expression of developmental genes in cancers.   
These channels are present at the plasma membrane of cancer cells where sodium currents have 
been recorded. With the exception of NaV1.6 in Ewing sarcoma cells (Hernandez-Munoz et al., 2016), 
all NaVα isoforms have been shown to bear oncogenic properties, promoting cancer cell invasion in 
vitro, as well as other behaviours associated with metastasis, such as the acquisition of elongated and 
mesenchymal-like phenotypes, directed migration, proliferation, regulation of endocytosis, control of 
intracellular and perimembrane pH and extracellular matrix degradation (Yang et al., 2012, Hernandez-
Plata et al., 2012, Roger et al., 2003, Grimes et al., 1995, Fraser et al., 2005, Gillet et al., 2009, Mycielska 
et al., 2003, Djamgoz et al., 2001, Brisson et al., 2013). In addition, NaVα subunits promote tumour 
growth, invasion, and metastasis in in vivo rodent models (Nelson et al., 2015b, Driffort et al., 2014, 
Batcioglu et al., 2012, Yildirim et al., 2012). Comparative studies performed in different cancer types 
indicate the involvement of these NaVα isoforms in similar functional properties, arguing for isoform-
independent signalling pathways. The activity of the channels at the plasma membrane appears to be 
critical. Indeed, Navα subunits are functionally active in cancer cell lines and primary tumour cells 
cultured in vitro, as well as in murine tumour xenograft tissue slices in vivo (Fraser et al., 2005, Roger 
et al., 2003, Hernandez-Plata et al., 2012, Nelson et al., 2015b) and their inhibition, using different 
drugs and small molecules such as TTX, ranolazine, phenytoin, Cn2 or PF-05089771, inhibit invasion 
(Nelson et al., 2015a, Nelson et al., 2015b, Driffort et al., 2014, Batcioglu et al., 2012, Yildirim et al., 
2012, Lopez-Charcas et al., 2018, Roger et al., 2003, Roger et al., 2007, Liu et al., 2019).   
Importantly, the membrane potential (Vm) of cancer cells is typically relatively depolarised compared 
to terminally differentiated non-cancer cells (Yang and Brackenbury, 2013). At this range of Vm, NaVα 
channels would be expected to be predominantly in the inactivated state. However, in cancer cells the 
Vm is generally between -40 and -30 mV and is situated in a window of voltage which provides a small 
non-inactivating persistent Na+ current flowing into the cell locally increasing intracellular Na+ 
concentration (Yang et al., 2012, Roger et al., 2003, Campbell et al., 2013). Recently a Na+-dependent 
intracellular signalling pathway, involving Salt-inducible kinase 1, has been proposed to account for 
pro-invasive effects of NaVα (Gradek et al., 2019).   
The main role attributed to Na+ is to serve as a mere mediator of the membrane potential, in excitable 
as well as in non-excitable cells. It is also characterized to support ions (among which Na+/K+, Na+/Ca2+, 




(Na+/glucose for example). The role of second messenger is mostly attributed to the Ca2+ ion, for which 
a lot of specific probes and tools have been developed over the last twenty years. In contrast, no direct 
and specific biological sensors for Na+ have been identified, and tools to study Na+ evolution still lack 
sensitivity or dynamics. Yet, there is some evidence suggesting that Na+ could act as a second 
messenger per se and might regulate several important signalling pathways in normal cells. Indeed, 
recent data support a direct role of Na+ in controlling kinases activity (Jaitovich and Bertorello, 2010), 
membrane fluidity and protein diffusion through an interaction with phospholipids (Hernansanz-
Agustin et al., 2020) or to induce inflammatory stress (Amara et al., 2016). Therefore, this raises the 
possibility that Na+ could also serve as a second messenger in cancer cells to activate signalling 
pathways promoting aggressiveness. To further support this hypothesis, it is worth mentioning that 
early studies questioned the involvement of intracellular Na+ content and the consequences on 
malignant cell proliferation, invasive capacities and the development of metastases (Cone, 1974). 
Indeed, much higher Na+ concentrations have been recorded in tumour cells, as compared to non-
cancer cells by energy-dispersive X-ray microanalyses (Cameron et al., 1980) as well as by 23Na-
magnetic resonance imaging (Ouwerkerk et al., 2007, Jacobs et al., 2004, Zaric et al., 2016) and was 
proposed to serve as an indicator of malignancy.   
The inward Na+ current may also further depolarise the Vm which might also participate in promoting 
migration. In support of this hypothesis, it was demonstrated in breast cancer cells that NaV1.5 
sustained Vm depolarization which activated the RhoGTPase Rac1, subsequently inducing cytoskeletal 
reorganization and cellular migration (Yang et al., 2020) (Figure 2). While there is clear evidence that 
NaVα channels expressed at the plasma membrane are critical in the acquisition of oncogenic 
properties, the discovery of splice variants with expression restricted to intracellular compartments, 
such as endosomes, phagosomes or lysosomes, (Lopez-Charcas et al., 2018, Carrithers et al., 2009) 
suggests a more complex role.  
  
b- (More than) Auxiliary NaVβ subunits   
The main NaVβ-encoding gene found to be upregulated in cancers is SCN1B, encoding for the NaVβ1 
subunit (Diss et al., 2008, Nelson et al., 2014, Bon et al., 2016, Sanchez-Sandoval and Gomora, 2019). 
On the other hand, there are multiple reports showing the downregulation of SCN4B (NaVβ4) 
(Hernandez-Plata et al., 2012, Bon et al., 2016, Diss et al., 2008, Gong et al., 2018, Sanchez-Sandoval 




The NaVβ1 subunit has been shown to increase cancer proliferation, cell adhesion, increase neurite-
like process outgrowth formation, and promote cancer cell invasion, whilst slowing migration in vitro 
(Nelson et al., 2014, Chioni et al., 2009, Bon et al., 2016, Sanchez-Sandoval and Gomora, 2019). In vivo, 
NaVβ1 overexpression increases angiogenesis and reduces apoptosis, thus increasing tumour growth 
and metastasis (Nelson et al., 2014). Taken together, these results are in favour of a pro-cancerous role 
of NaVβ1 and the effects appear to be dependent in part on the regulation of the NaVα pore-forming 
subunit and as well as being dependent on the extracellular CAM motif (Nelson et al., 2014). NaVβ2 
expression in prostate cancer cells also increases process extension, adhesion, invasion and migration 
in vitro, but reduces tumour take in vivo (Jansson et al., 2014, Jansson et al., 2012). Conversely, NaVβ3 
and NaVβ4 may function as tumour suppressors. The SCN3B gene contains p53 response elements and 
NaVβ3 suppresses colony formation and promotes chemotherapy-induced apoptosis in a p53-
dependent manner (Adachi et al., 2004). NaV β4 expression is downregulated in breast, colorectal, 
lung, cervical, prostate tumours and papillary thyroid cancer compared with normal tissue (Hernandez-
Plata et al., 2012, Bon et al., 2016, Diss et al., 2008, Gong et al., 2018, Sanchez-Sandoval and Gomora, 
2019). In addition, NaVβ4 functions as a tumour and metastasis suppressor gene in vivo (Bon et al., 
2016). This tumour-suppressing function occurs via β4mediated control of RhoA GTPase activation 
(Bon et al., 2016) (Figure 2).  
  
 III-  NaVα as anticancer targets for repurposed drugs and new small inhibitory molecules  
NaVα are attractive drug targets because of the broad therapeutic potential of their blockers. 
Considering the fact that NaVα are expressed in metastatic cells in various tumours, significant effort 
has been made to develop NaVα blockers as potential drugs for cancer treatment. This section of the 
review focuses on such efforts that took place in the past 10 years. These efforts for blocker 
development can broadly be classified in to two sections. 1) Repurposing drugs that are FDA-approved 
for other clinical uses (local and general anaesthetics, antiepileptic and anticonvulsant, antiarrhythmic 
drugs). 2) Rational design and development of novel NaVα blockers for cancer treatment.  
  
a- Repurposing of FDA-approved NaVα blockers  
There are numerous existing NaVα inhibitors licensed for clinical use. In several cases NaVα 
inhibition is considered an off-target effect of these drugs. For example, tricyclic antidepressants, 
including amitriptyline, inhibit the serotonin transporter, but also inhibit several neurotransmitter 




considered the primary mechanism of the drug’s intended therapeutic effect. This is true for several 
anti-seizure medications (e.g. phenytoin and carbamazepine) and all of the local anaesthetics, although 
these too have additional off-target actions. Regardless of whether it is a primary or secondary effect 
of a licensed medication, NaVα inhibition might be beneficial in patients with cancers associated with 
NaVα expression. This raises the intriguing possibility that approved NaVα inhibiting drugs might be 
repurposed to treat cancer.   
Benefits of repurposing approved medications include prior knowledge of their mechanisms of action 
and the availability of toxicology and safety data, thereby avoiding the need for drug discovery and 
early phase clinical trials. Drawbacks include limited potential for developing intellectual property, 
leading to a lack of both funding potential and industry involvement (Pushpakom et al., 2019). 
Nevertheless, despite the potential drawbacks, there are some notable successes and a well-trodden 
pathway to repurposing is through the use of electronic health records to link prescribing data to 
potentially beneficial health outcomes. A good example of the impact of this type of retrospective 
clinical analysis is the identification of an association of aspirin-use with reduced risk of colon cancer 
(Dube et al., 2007). Similar approaches are being used in studies exploring a possible relationship 
between NaVα inhibitors and outcomes in cancer patients.  
  
Anti-seizure and class 1 antiarrhythmic NaVα inhibitors  
A recent study, using retrospective clinical analysis to explore the possibility of a beneficial effect of 
NaV inhibiting medications, examined several class 1 antiarrhythmic and antiseizure medications in 
patients with breast, bowel or prostate cancer (Fairhurst et al., 2015). The combined analysis revealed 
that these medications (including Class I antiarrhythmic drugs, lamotrigine, carbamazepine phenytoin, 
and valproate) were collectively associated with decreased median time to death compared to the 
control patient group, with significantly increased mortality in the drug group. This study clearly does 
not support the idea of repurposing antiseizure NaVα inhibitors in the treatment of breast, bowel or 
prostate these cancers. However, as the authors pointed out, the causes of death were not available 
in the large primary care dataset and co-morbidities were among the likely confounding factors. In 
many cases, patients treated with NaVα inhibiting drugs will be suffering from life-threatening 






Analgesic NaVα inhibitors  
There has been considerable recent interest in the idea that anaesthetics and analgesics used during 
surgical tumour excision might influence subsequent cancer recurrence. Surgery can cause the release 
of tumour cells into the circulation and the number of postsurgical circulating cancer cells is known to 
be a negative prognostic indicator of disease-free survival (Yu et al., 2018). The perioperative period, 
i.e. immediately before, during and after surgery, may therefore be an opportune time for 
interventions that inhibit the potential for metastatic invasion. A variety of drugs are typically 
administered during surgery including general anaesthetics, analgesics, anti-muscarinic and 
neuromuscular blockers. Some of these, such as inhalational general anaesthetics, may have the 
potential to worsen outcomes by suppressing the immune response (Stollings et al., 2016). By contrast, 
local anaesthetics may provide more favourable outcomes. Local anaesthetics are often administered 
regionally to provide blockade of afferent nociceptive fibres entering the spinal cord. Several 
retrospective clinical studies suggest that regional analgesia during breast and prostate cancer surgery 
increases disease free survival (Forget et al., 2019). The use of regional anaesthesia diminishes or 
abolishes the need for general anaesthetic during surgery. It was therefore initially hypothesised that 
the general anaesthetic sparing effect of regional analgesia with local anaesthetics accounts for the 
apparent beneficial effect (Sessler et al., 2008). However, a recent large prospective multicentre trial 
comparing outcomes after breast cancer surgery under inhalational anaesthesia with or without 
paravertebral analgesia by ropivacaine or levobupivacaine revealed no difference in disease free 
survival (Sessler et al., 2019).   
Most of the ongoing clinical trials exploring the impact of anaesthetic technique on cancer outcomes 
are predicated on the idea that the potential benefit of local anaesthetics is conferred indirectly 
through their inhalational anaesthetic sparing effect. However, it is possible that local anaesthetics 
such as lidocaine, ropivacaine and levobupivacaine provide a direct beneficial effect through NaVα 
inhibition (Baptista-Hon et al., 2014, Elajnaf et al., 2018). If this is the case then a more direct approach 
for administering these drugs directly onto the tumour may prove to be beneficial. Lidocaine, in 
addition to being a local anaesthetic, is also used intravenously as a class 1b antiarrhythmic agent and 
a circulating analgesic. Ongoing clinical trials will test whether lidocaine delivered directly onto breast 
tumours prior to excision, or intravenously during the perioperative period for colon cancer surgery 
will prolong postoperative disease-free survival (NCT01916317, R.A Badwe, 2013; NCT02786329, D. 
Ionescu, 2016). We await the outcome of these trials with interest and note that there are several 
other approved NaVα inhibiting drugs that should be examined in retrospective clinical studies for 





b- Rational design of small molecule NaVα blockers   
Rational designing of NaVα inhibitors has been difficult since detailed structural information of 
drug binding sites for this integral membrane protein were lacking until very recently. Therefore, early 
effort for the discovery of NaVα blockers mainly relied on strategies such as ligand-based drug design, 
natural product based drug design, in silico screening and similarity searches. However, recent reports 
on the structures of human and bacterial NaVα and bound ligands shed light on their binding site 
(Cervenka et al., 2018, Nguyen et al., 2019, Pan et al., 2018, Payandeh et al., 2011, Shen et al., 2017, 
Shen et al., 2018, Shen et al., 2019). These reports will certainly aid in the structure-based design and 
discovery of NaVα blockers. A summary of the available reports on the identification and evaluation of 
NaVα blockers for potential use in cancer therapy follows.    
One such effort to identify NaVα blockers used a pyrrole-imidazole marine alkaloid, clathrodin (Hodnik 
et al., 2013). Clathrodin was originally isolated from the Agelas clathrodes sponge. Several 
conformationally restricted analogues of clathrodin containing a 4,5,6,7-tetrahydrobenzo [d] thiazol2-
amine moiety are blockers of NaV1.3, NaV1.4, NaV1.5 and NaV1.7 channels. These compounds display 
state-dependent inhibitory activity of these channels at low micromolar concentrations. The most 
active compound (4e, Figure 3) identified from this study represents a novel selective blocker of NaV1.4 
channel with an IC50 value of 8 µM.  The use of clathrodin analogues as a template for ligand based 
virtual screening of commercially available ZINC library of compounds using ROCS software, identified 
two potent lead compounds 2 and 16 (Tomasic et al., 2013) (Figure 3). These blocked INa produced by 
NaV1.7 with IC50 values of 7 μM and 9 μM, respectively.   
Plant derived polyphenolic natural products have also been reported as NaVα inhibitors. For example, 
the plant phenolic, resveratrol, (Figure 3) found at high concentrations in red grapes inhibits NaVα with 
an IC50 value of 50 μM (Fraser et al., 2014). Resveratrol also suppresses lateral cell motility by up to 
25%, transverse cell motility by 31%; and cell invasion by 37%, without affecting cellular proliferation 
or cell viability of MAT-LyLu cells. Another similar phenolic is caffeic acid phenethyl ester (CAPE, Figure 
3) isolated from honeybee propolis. CAPE blocks NaV activity in several invasive cancer cell lines 
including breast (MDA-MB-231 and MDA-MB-468), colon (SW620) and non-small cell lung cancer 
(H460). Motility and invasion of MDA-MB-231 cells were reduced by up to 14% and 51%, respectively 
by CAPE at 1 μM without affecting cell proliferative activity (Fraser et al., 2016).  
Shaheen et al. used an in silico approach to identify NaVα blockers with superior pharmacological 




conducted a similarity search in the PubChem database with PHT and CBZ as query molecules using 
the Tanimoto based similarity search. The search was further refined by docking of these molecules 
into the binding site of the homology model of SCN1A using MolDock program. This study identified 
high affinity compounds similar to PHT and CBZ. The lead compounds were further evaluated for 
toxicity profiles and biological activity. Two of the best compounds identified by this study, NSC403438 
and AGN-PC-0BPCBP (Figure 3) demonstrated better binding affinity to NaVα compared to PHT and 
CBZ, with NSC403438 being a superior inhibitor of INa with lower toxicity, better IC50 value and optimal 
bioactivity.   
NaVα inhibitors were also derived from the natural product, crambescin (Nakazaki et al., 2016). 
Enantiomerically pure crambescin A, B and C carboxylic acid derivatives were synthesized and 
evaluated for their ability to block NaVα. Structure activity relationship studies revealed that the natural 
enantiomer of crambescin B, carboxylic acid, (Figure 3) is the most active compound with activity 
comparable to TTX. The cyclic guanidinium moiety present in this molecule is indispensable for its 
activity.   
In 2018, Dutta et al. utilized a highly predictive, comprehensive 3D-QSAR model for the design of NaVα 
blockers (Dutta et al., 2018). The NaVα binding data (IC50) for 67 compounds were used to train a 
comprehensive CoMFA model, which effectively covered 3D space and spanned over 4 orders of 
magnitude in biological activity. Potency predictions by this model have been highly accurate for the 
more than 30 compounds that were synthesized and evaluated. Five compounds shown or predicted 
to have low nanomolar NaVα binding were further evaluated for the inhibition of hNaV1.5e currents in 
individual breast cancer MDA-MB-231 cells. Of these, two lead compounds, 1 and 4 (Figure 3) were 
found to be most effective in whole cell patch-clamp studies and showed significant invasion inhibitory 
activities at concentrations as low as 1 µM without affecting cell viability.  
Boezio et al. reported several sulfonamides with highly selective NaV1.7 blockade activity (Boezio 
et al., 2018). This novel series of blockers contained a triazole sulfone which served as a bioisostere for 
the acyl sulfonamide group. This work resulted in the discovery of a series of potent NaV1.7 blockers 
with selectivity over NaV1.5 and favourable pharmacokinetic properties in rodents. An example of such 
a blocker is compound 35 (Figure 3). In the same year, Yapa et al. reported a known inhibitor of TRPM8, 
N-(3-aminopropyl)-2-{[(3-methylphenyl) methyl]oxy}-N-(2-thienyl methyl)benzamide (AMTB, Figure 3) 
as a NaVα blocker in breast cancer MDA-MB-231 cells (Yapa et al., 2018). AMTB decreased viable cell 
number in MDA-MB-231 and SK-BR-3 breast cancer cell lines and also reduced the migration of MDA-
MB-231 cells. These studies provided the evidence that these effects are not related to TRPM8 




investigated the potential effects of a natural flavanone, naringenin (Figure 3) on the motility of MAT-
LyLu cells in 2018 (Gumushan Aktas and Akgun, 2018). This study revealed that naringenin inhibited 
cell proliferation at higher concentrations (75 μM), whereas it decreased the movement of MAT-LyLu 
cells at low concentrations (5 μM and 10 μM). Moreover, naringenin inhibited cell motility by reducing 
the expression of the SCN9A gene at the mRNA level. In conclusion, naringenin was found to have 
direct or indirect blocking activity on the SCN9A encoded channel. Most recently, in 2019, Wang et al. 
has reported NaV1.7 channel blockers using a comparative molecular field analysis (CoMFA) model for 
the binding of ligand to NaVα was generated based on diverse set of compounds. No channel current 
blockade data was presented in the paper.  
However, there was an extensive anticancer evaluation of the identified lead compounds S0154 and 
S0161 (Wang et al., 2019). Both showed anticancer and anti-metastatic effects against PC3 prostate 
cancer cells and significantly inhibited cell viability, with IC50 values in the range of 5-26 μM. Both these 
compounds inhibited the expression of NaVα, increased the intracellular level of Na+, and caused cell 
cycle arrest in G2/M phase. The compounds also inhibited the invasion of PC3 cells. Furthermore, 
S0161 inhibited the PC3 tumour growth of by about 51% in an in vivo xenograft model (Wang et al., 
2019).  
In conclusion, there have been major advances in NaVα targeted drug discovery over the last 
decade. Specific NaVα isoforms have been implicated in the metastasis development of a variety of 
tumours raising the possibility of developing tumour selective drugs. Recent advances in the discovery 
of high-resolution crystal and cryo-EM structures of NaVα should further advance the field with 
structure-based drug design efforts.   
  
 IV-  NaVα as targets for nutritional management of cancers  
Cancer is a metabolic disease which depends on bioenergetic parameters (Penkert et al., 2016). 
Cancer progression is generally associated with the survival of cancer cells under conditions of low 
oxygen levels and nutrient deprivation, and relies on metabolic adaptations (Dumas et al., 2017, 
Hanahan and Weinberg, 2011). These metabolic adaptations allow cancer cells to survive the pressure 
of environmental conditions and to fulfil the high energy demands associated with their high anabolic 
activity (Payen et al., 2016, Porporato et al., 2016). Also, this metabolic switch towards an aerobic 
glycolysis brings selective advantages by promoting invasive activities and metastatic properties 
(Brisson et al., 2012, Webb et al., 2011). Furthermore, the metabolic reprogramming does not only 




deregulation of the energetic balance in patients, called tumour cachexia (Fearon et al., 2012). This 
devastating syndrome, initially triggered by the release of soluble tumour factors and the participation 
of a systemic inflammation, is characterized by anorexia, the loss of skeletal muscle mass, in some 
cases with the loss of adipose tissue mass, and a general weakening of patients, impeding their quality 
of life and decreasing the tolerance to antineoplastic therapies (Fonseca et al., 2020, Biswas and 
Acharyya, 2020). In this context, bringing a nutritional support to patients is required to allow holding 
the most efficient possible treatment. Nutritional interventions are mostly aimed at preventing the 
wasting of body compartments in patients, but could also be a source of active anti-cancer molecules. 
Furthermore, diet represents a controllable component of the environment and brings promising 
strategies to increase treatment efficacy in combination with conventional chemotherapeutics. Some 
dietary compounds have also been shown to decrease the risk of carcinoma development and may 
prolong the survival of patients (Dumas et al., 2017).  
As pointed out in the previous section, several natural compounds in the diet, such as resveratrol and 
caffeic acid phenethyl esters, are effective at inhibiting NaVα subunits (Fraser et al., 2016, Fraser et al., 
2014). Dietary lipids have also been proposed to inhibit NaVα and to modulate cancer progression. 
Indeed, dietary lipids incorporate into cellular membrane and alter NaVα or their pharmacology (Agwa 
et al., 2018, D'Avanzo, 2016). Among dietary lipids, long chain n-3 polyunsaturated fatty acids (n-3 
PUFA) have been described in epidemiological studies to delay or prevent the appearance of breast 
cancer (Rose et al., 1996, Bougnoux et al., 2010). From both in vivo and in vitro studies, n-3 PUFA have 
been reported to induce multiple anti-tumour effects and their dietary consumption was associated 
with a lower risk of cancers, such as breast or colorectal cancers (Bougnoux, 1999, Bougnoux et al., 
2010, Eltweri et al., 2016). Even though n-3 PUFA were suggested to prevent prostate cancer (Moreel 
et al., 2014, Li et al., 2017), their beneficial effect remains to be demonstrated through more 
intervention trials or observational studies (Aucoin et al., 2016). A pilot study showed that fatty acid 
composition of breast adipose tissue differed according to breast cancer focality : low levels of the two 
long chain n-3 PUFA docosahexaenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3) 
were associated with tumour multifocality, which is considered a marker of cancer aggressiveness 
(Ouldamer et al., 2016a). These results could indicate that differences in adipose tissue concentration, 
a surrogate of past dietary uptake, may contribute to mechanisms influencing cancer progression.  
Long-chain n-3 PUFA have been proposed to increase tumour sensitivity to chemotherapeutic agents 
with no sensitization of normal tissues and no additional side effect (Bougnoux et al., 2010). As such, 




anthracyclines, taxanes or radiotherapy in mammary tumour models (Bougnoux et al., 2010, Hajjaji et 
al., 2012, Hajjaji et al., 2011, Ouldamer et al., 2016b).  
N-3 PUFA have also been shown to have anti-invasive and anti-metastatic properties 
(Blanckaert et al., 2010, Gillet et al., 2011, Rose et al., 1997, Rose et al., 1994, Bougnoux et al., 2010). 
On the other hand, they are capable of modulating the activity of NHE exchangers (Besson et al., 1996, 
Lacroix et al., 2008) and ion channels (Tillman and Cascio, 2003, Jude et al., 2003). Interestingly, in 
expression systems and in native rat cardiomyocytes, the activity of NaV1.5 was initially found to be 
inhibited by n-3 PUFA (Kang and Leaf, 1996, Kang et al., 1997), and in initial studies have proposed that 
these effects could be mediated by a directly binding of n-3 PUFA to specific residues of the channel 
(Xiao et al., 2001, Xiao et al., 1998). Therefore, n-3 PUFA could also exert their beneficial effects on 
cancers through a reduction of NaV1.5 (Pignier et al., 2007, Gillet et al., 2011). However, contrasting 
results were obtained in human breast cancer cells in which INa was not inhibited by acute applications 
of n-3 PUFA, even at high concentrations (30-50 µM) (Wannous et al., 2015) at which they also have 
anti-proliferative effects (Barascu et al., 2005). This discrepancy might be due to the fact that cancer 
cells mostly express the hNaV1.5e neonatal splice variant (Fraser et al., 2005). However, growing breast 
cancer cells in the presence of low doses of DHA (0.5 to 10 µM) reduced SCN5A gene expression and 
levels of NaV1.5 proteins and INa (Wannous et al., 2015, Isbilen et al., 2006). This inhibition of SCN5A 
expression was mediated by the lipid-sensitive nuclear receptor Peroxisome Proliferator Activated 
Receptor –β (PPAR-β). Correlatively, the inhibition of NaV1.5 activity was also responsible for a reduced 
activity of the downstream protagonist NHE-1, thus decreasing H+ efflux, preventing extracellular 
matrix degradation proteolytic activity and inhibiting breast cancer cell invasiveness (Wannous et al., 
2015). A recent report also demonstrated the efficacy of EPA to reduce migration and proliferation of 
ovarian cancer cells by inhibiting NaV1.5 (Liu et al., 2018).   
Such regulations concerning other NaVα involved in cancer properties, i.e. NaV1.6 and NaV1.7, should 
be investigated. It is also of interest to note that n-3 PUFA, through the activation of PPAR-γ, have been 
shown to down-regulate the expression of NHE-1 and reduce cancer colony growth (Kumar et al., 
2009). Furthermore, incorporation of n-3 PUFA into phospholipids induces changes in the physico-
chemical properties of cell membranes (Yaqoob and Shaikh, 2010) which in turn affects NHE1 activity 
(Dendele et al., 2014).  
Further to these effects on NaV channels and downstream signalling pathways, it should be mentioned 
that n-3 PUFA might exert a multiplicity of actions by interfering with several signalling pathways, 




is not obligatorily detrimental and pleiotropic effects might increase the efficacy of the anticancer 
treatment.  
N-3 PUFA supplementations were proposed to have beneficial effects in reducing mammary tumour 
growth, by slowing down cancer cell proliferation (Barascu et al., 2005). N-3 PUFA treatment was 
demonstrated to inhibit cyclin B1 and the expression of the cell division cycle 25C phosphatase, which 
dephosphorylates cyclin-dependent kinase 1 (Barascu et al., 2005). In addition, the nuclear receptor 
PPARβ appeared to regulate the DHA-related inhibition of MDA-MB-231 and MCF-7 cells proliferation. 
This allowed identifying PPARβ as an important protagonist in the inhibition of breast cancer cell 
proliferation and mammary tumour growth under DHA-enriched diet (Wannous et al., 2013). N-3 PUFA 
have been proposed to regulate autophagy in cancer cells, and as such could be involved in both 
survival and apoptosis, depending on the carcinogenetic phase and on the treatment context (Ferro et 
al., 2020).  DHA was found to induce apoptosis in cancer cells (Jing et al., 2011). DHA-induced 
autophagy was associated with p53 loss, with the activation of AMPK and with the decrease in the 
activity of mTOR. Autophagy inhibition suppressed apoptosis, and autophagy induction further 
enhanced apoptosis in response to DHA treatment (Jing et al., 2011). There is evidence that n-3 PUFA 
may inhibit the expression of EMT markers and reduce associated invasive properties in cancer cells 
(D'Eliseo et al., 2016, Yin et al., 2016). Altogether, these effects could bring beneficial values to delay 
the appearance/diagnosis of a primary tumour, and as such be of interest in primary prevention.   
N-3 PUFA, which are highly peroxidizable, were also proposed to improve the efficacy of anticancer 
treatments by amplifying oxidative stress generated by anthracyclines or radiotherapy (Bougnoux et 
al., 2009). The acquisition of resistance to chemotherapeutic agents represents an important limitation 
in cancer. Resistance to taxanes has been proposed to depend on the induction of signalling pathways 
such as PI3K/Akt and ERK1/2, which promote survival and cell growth in human cancer cells. In 
docetaxel-treated MDA-MB-231 cells, phosphorylated-ERK1/2 levels were increased by 60% in both 
membrane and nuclear compartments, compared to untreated cells and ERK1/2 activation depended 
on PKCε and PKCδ activation. In comparison, in cells treated with DHA, docetaxel was unable to 
increase PKCε and PKCδ levels, thus resulting in the reduction of ERK1/2 phosphorylation and the 
increase in docetaxel efficacy (Chauvin et al., 2016). In addition to these effects, n-3 PUFA were 
proposed to increase the efficacy of the chemotherapeutic treatment by remodelling the tumour 
vascular network, thereby improving the delivery of anticancer drugs within the tumour (Kornfeld et 
al., 2012). These results support the hypothesis that n-3 PUFA, which do not induce any toxic effect, 





 V-  Conclusions and perspective for the treatment of cancers  
There is now clear evidence that the abnormal expression of NaV subunits occurs during 
carcinogenesis is associated with cancer progression towards metastatic states. Several different NaVα 
play a role, including NaV1.5, NaV1.6 and NaV1.7, but the intracellular signaling pathways they regulate 
appear to be the same or very similar in all studied cancer types, leading to the induction of invasive 
properties. The activity of such channels at the plasma membrane, and consequent INa, appear critical. 
Therefore, the inhibition of NaVα in cancer cells represents a new anti-cancer strategy which could be 
achieved in several ways alone or in combination: repurposing existing NaVα– inhibitory drugs, 
developing new small inhibitory molecules, and through dietary interventions. As shown above, NaVβ 
subunits also have important roles in cancer cell biology and in cancer progression, acting both as 
auxiliary subunits of NaVα and as CAMs. However, they do not exert a recordable activity per se and 
their direct “inhibition” or “activation” would be challenging. Therefore, dietary strategies aiming at 
controlling their expression, i.e. reducing the expression of SCN1B and SCN2B, while maintaining the 
expression of SCN3B and SCN4B, might represent powerful strategies.  For this purpose, future studies 
aiming at unravelling transcriptional and epigenetic regulators will be of high interest.  
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Figure legends  
  
Figure 1: Expression of NaVα in carcinoma and role in invadopodial activity and invasion of 
extracellular matrices.  
Progression of precancerous into cancer cells is illustrated in the context in the malignant 
transformation of colon epithelium. Transformed cells have lost cell polarity, replication control, cell-
cell adherent junctions and they acquired a mesenchymal pro-invasive phenotype. Migrating cancer 
cells develop a specialized actin-based membrane protrusions called “invadopodia” that facilitate cell 
invasion by providing a coupling of focal extracellular matrix (ECM) degradation together with a 
directional cell movement. NaV channels are expressed in invadopodial structures, co-localizing with 
the Na+/H+ exchanger type 1 (NHE1). Activity of NaV channels enhances the extrusion of protons by 
NHE1 and therefore the acidification of the peri-invadopodial microenvironment, thus favouring both 
secretion and activity of ECM proteases such as cysteine cathepsins and matrix metalloproteinases 
(MMPs). Cancer cell resting potential (Vm) is around -40 mV, in a window of voltage of NaV channels 
(overlap between activation and steady-state inactivation curves) in which a small proportion of 
channels are activated but non-inactivated, thus generating a small but continuous Na+ influx through 
a so-called “window sodium current”. NaV channels are also proposed to increase the intracellular 
levels of Ca2+ ions by the functioning of Na+/Ca2+ exchanger (NCX) in a “reverse mode”. Thus, the 
increase in the intracellular concentration of Na+, and Ca2+, sustains SRC kinase activity leading to the 
polymerization of acting filaments and the formation of invadopodial structure.   
  
Figure 2: Participation of NaVα and/or NaVβ in pro-metastatic signalling pathways.   
NaVα subunit over-expression and activity in cancer cells trigger biochemical or an electro-biochemical 
cascades leading to the acquisition of a pro-invasive cell phenotype. NaV is co-localized with NHE1 in 
caveolin-1 (Cav-1)-containing lipid rafts and promotes the efflux of protons. NaV activity can be further 
stimulated by the use of pharmacological activators such as veratridine (inhibitor of the inactivation 
phase). Activity of NaVα subunits leads to a cAMP-independent activation of protein kinase A (PKA) 
that activates the cytosolic small GTPase Ras-related protein 1 (Rap1A/B) and the extracellular signal-
regulated kinases (ERK1/2). The transcription factor (TF) metastasis-associated in colon cancer 1 
(MACC1) is activated by the p38/NF-κβ signalling while the TFs c-jun, ELK1 and ETS1 are activated by 
ERK1/2 and the activation of the zinc finger protein SNAI1 through a NaVαdependent mechanism 
regulating the expression of genes associated with cytoskeleton reorganization, cell motility, 
extracellular matrix degradation and cell invasiveness. It has been demonstrated that MACC1 
upregulates the expression of the SLC9A1 gene, encoding for NHE1, thus enhancing its activity at 
plasma membrane. On the other hand, the electro-biochemical triggering begins with a resting 
potential depolarization due to the activity of NaVα subunits promoting the activation and recruitment 
of the small GTPase Ras-related C3 botulinum toxin substrate 1 (Rac1) at the leading edge of migrating 
cells. Transforming growth factor beta 1 (TGF-β1) increases the expression levels of NaV channels genes 
(SCNxA) while ring finger protein 1 (RING1B), RE1 silencing transcription factor (REST), histone 
deacetylase 2 (HDAC2) and salt inducible kinase 1 (SIK-1), as well as the n-3 polyunsaturated fatty acids 
n-3 (PUFA), repress their expression. SIK-1 also impairs the functioning of NHE1 exchanger. The 
“auxiliary subunit” NaVβ4 is expressed in normal epithelial cells but is importantly down-regulated in 




of the intracellular C-terminus domain, triggers the acquisition of an amoeboid-mesenchymal hybrid 
phenotype dependent of the small GTPase Ras homolog family member A (RhoA). NaVβ1 proteins have 
a dual role in cancer cells acting as cell adhesion molecules (CAMs) reducing cell migration and 
proliferation. However, it has also been demonstrated that NaVβ1 promotes tumour growth, 
metastasis and vascularization via the proto-oncogene tyrosine-protein kinase Fyn. The Rho-associated 
protein kinases (ROCK1/2) negatively regulate the expression of NaVα subunits, therefore, silencing or 
inhibition of these repressors restore NaV channels activity promoting an aggressive cell phenotype. 
Pharmacological intervention with FDA-approved drugs or new design small-molecule lead compounds 
against NaV channels represent a promising strategy to decrease sodium channels-associated 
metastases.   
  
Figure 3: Chemical structures of known NaVα blockers with anticancer effects.  
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Table and legend  
  
Table I: Expression and identified roles of pore-forming NaVα and auxiliary NaVβ in cancer  
  
*Cancer tissue vs non-cancerous tissue  
#Highly invasive cell line vs normal immortalized cell line  
†In vitro  







Isoform Expression levels 
 







Lymph nodes  
from CRC  
  
Unknown, unknown  Lin et al., 2019  
NaV1.2  Upregulated* (Protein)  Liver  Unknown, unknown  
The Human protein  
Atlas  
(www.proteinatlas.org)  
NaV1.3  Upregulated* (mRNA)  Ovarian  Unknown, unknown  Gao et al., 2010  
NaV1.4  Upregulated* (mRNA)  Cervix  Unknown, unknown  Diaz et al., 2007  
NaV1.5  
Upregulated*# (mRNA, 
protein, INa+)  
Breast  
  
↑Invasion†‡   
▪ Through an increased Src 
kinase activity promoting 
invadopodial formation and 
favoring an allosteric activation 
of NHE-1, extracellular 
acidification and enhanced 
activity of cysteine−cathepsins  
proteases  
▪ Boosting the EMT transition via 
SIK1  
▪ Generating a sustained plasma 
membrane depolarization that 
leads to Rac1 activation and 
cytoskeleton reorganization ▪ 
Increasing MMP9 expression 
and reducing apoptosis  
Roger et al., 2003,  
Fraser et al., 2005,  
Brackenbury et al.,  
2007, Gillet et al.,  
2009, Brisson et al.,  
2011, Yang et al., 2012,  
Brisson et al., 2013,  
Driffort et al., 2014,  
Nelson et al., 2015a,b,  
Gradek et al., 2019,  
Yang et al., 2020,   
Colorectal  
↑Invasion†   
Through the regulation of the 
transcriptional pathway 
PKA/ERK/c-jun/ELK-1/ETS-1   
House et al., 2010,  
Baptista-Hon et al.,  
2014, House et al.,  
2015, Guzel et al.,  




Ovarian   
↑Migrajon† ↑Invasion†  
↑Proliferajon†  
▪ By increasing the window 
current and depolarization of 
resting potential  
Gao et al., 2010, Liu et 
al., 2018  
Leukemia  
↑Invasion†  
▪ Endosomal acidification and 
enhanced phagocytosis via 
calcium signaling   
Fraser et al., 2004,  
Carrithers et al., 2007,  
Carrithers et al., 2012,  
Rahgozar et al., 2013,  
Jones et al., 2014,  
Huang et al., 2015  
 
NaV1.6  
Upregulated*# (mRNA,  
protein, INa+)  
Cervix  
↑Invasion†   
▪ Boosted activity of MMP2 and  
NHE-1  
Diaz et al., 2007,  
Hernandez-Plata et al.,  
2012, Lopez-Charcas et 
al., 2018 
Leukemia  
↑Invasion†   
▪ Invadopodial formation and 
enhanced activity  
Carrithers et al., 2009  
Melanoma  
↑Invasion†   
▪ Invadopodial formation and 
enhanced activity  
Carrithers et al., 2009  
  
Lymph nodes  
from CRC  
  
  
Unknown, unknown  
  
Lin et al., 2019  
Downregulated*# (mRNA, 
protein, INa+)  
Erwin sarcoma 
↓Migrajon† ↑Apoptosis†  
Through a repression of SCN8A 
by RING1B and maintaining low  
NF-κβ levels  
Hernandez-Munoz et 
al., 2016  
Colorectal  Unknown, unknown   Igci et al., 2015  
NaV1.7  
Upregulated*# (mRNA, 
protein, INa+)  
Prostate  
↑Invasion†  
▪ Cell motility increased via 
galvanotaxis 
Grimes et al., 1995, 
Diss et al., 2001, Diss 
et al., 2005, Yildirim et  






▪ Dysregulation of sodium 
homeostasis   
▪ Increase of [Na+]i and  
depolarization of cell  
membrane  
Roger et al., 2007  
Campbell et al., 2013  
Lung (SCLC)  
Unknown  
Participation in the formation of 
a neuroendocrine-like tumor cell 
phenotype  
Pancrazio et al., 1989,  
Blandino et al., 1995,  
Onganer et al., 2005  
Stomach  
↑Invasion†‡ ↑Tumour growth‡  
▪ Cancer progression through 
MACC1-mediated upregulation 
of NHE-1   
Xia et al., 2016  
Endometrial  
↑Invasion†‡↑Tumour 
growth‡↓Apoptosis‡ ▪Unknown  
Liu et al., 2018, Liu et 




Unknown, unknown   
▪ Proposed within a risk score 
with high prognostic value for 
overall survival   
Pan et al., 2017  
NaV1.8  Upregulated# (mRNA)  Lung (NSCLC)  Unknown, unknown   Roger et al., 2007  




Prostate  Unknown, unknown  Diss et al., 2008  
Breast  
↑Tumor growth†‡  
↑Vascularizajon‡ ↑Invasion†  
↓Apoptosis  
 ▪ β1 trans-homophilic adhesion  
triggering of cell process 
outgrowth via fyn kinase  
Nelson et al., 2014,  





By decreasing cell adhesion and 
facilitating cell migration  
Chioni et al., 2009  
Lung   
↑Invasion†  
By decreasing cell adhesion   
Campbell et al., 2013  





▪Acting as a cell adhesion 
molecule 
↓Proliferation† 
▪By increasing the population of 
cells in the G0/G1 phase in cell 
cycle 
Sanchez-Sandoval and  







▪ Promotion of bipolar cell 
morphology, enhanced cell 
adhesion and motility through 
association with neural 
substrates.  
↓Tumour volume in xenograft 
models‡  
Jansson et al., 2012,  






▪ Increase of a p53-dependent 
apoptotic pathway  






▪ Enhanced RhoA activity   
▪ Mediated by the intracellular  
C-terminus motif   
▪ Acquisition of a hybrid  
mesenchymal-amoeboid 
aggressive phenotype  
Bon et al., 2016  
Lung  Unknown, unknown  Bon et al., 2016  
Cervix  ↑Invasion†  
Sanchez-Sandoval and 
Gomora, 2019  
Thyroid  
Unknown  
▪ Its expression is an indicator of 
favorable recurrence-free 
survival  






























• Voltage-gated sodium (NaV) channels are aberrantly expressed in cancers tissues  
• NaV activity promotes aggressive progression of cancer cells  
• NaV channels are pharmacological targets for anticancer treatments  
• NaV expression / activity could be modulated by nutritional interventions  
